Development And Licensing Agreement With Abbvie To Develop Next-Generation Long-Acting Injectable Therapies

Medincell SA

16/04/2024 16:46

April 16 (Reuters) - Medincell SA  MEDCL.PA :
    * MEDINCELL SA - MEDINCELL WILL RECEIVE AN UPFRONT PAYMENT
OF $35
MILLION
    * MEDINCELL SA - WILL RECEIVE AN UPFRONT PAYMENT OF $35
MILLION
    * MEDINCELL ENTERS INTO STRATEGIC CO-DEVELOPMENT AND
LICENSING
AGREEMENT WITH ABBVIE TO DEVELOP NEXT-GENERATION LONG-ACTING
INJECTABLE THERAPIES
    * MEDINCELL SA - MEDINCELL AND ABBVIE WILL CO-DEVELOP, AND
ABBVIE
WILL COMMERCIALIZE UP TO SIX CUTTING-EDGE LONG-ACTING
INJECTABLES (LAI).
    * MEDINCELL SA - IS ELIGIBLE FOR UP TO $1.9 BILLION IN
POTENTIAL
DEVELOPMENT AND COMMERCIAL MILESTONES
    * MEDINCELL SA - MEDINCELL IS ALSO ELIGIBLE TO RECEIVE
MID-SINGLE
TO LOW-DOUBLE-DIGIT ROYALTIES ON NET SALES.
    * MEDINCELL SA - MEDINCELL IS ALSO ELIGIBLE TO RECEIVE
MID-SINGLE
TO LOW-DOUBLE-DIGIT ROYALTIES ON NET SALES
    * MEDINCELL SA - CO-DEVELOPMENT AND LICENSING AGREEMENT
COVERS UP
TO 6 PROGRAMS

Source text for Eikon:  ID:nBw16S2jza 
Further company coverage:  MEDCL.PA 

 ((Reuters.Briefs@thomsonreuters.com;))